Pharsight

Orgovyx is owned by Myovant Sciences.

Orgovyx contains Relugolix.

Orgovyx has a total of 6 drug patents out of which 0 drug patents have expired.

Orgovyx was authorised for market use on 18 December, 2020.

Orgovyx is available in tablet;oral dosage forms.

Orgovyx can be used as treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent, treatment of adult patients with advanced prostate cancer.

Drug patent challenges can be filed against Orgovyx from December, 2024.

The generics of Orgovyx are possible to be released after 29 September, 2037.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280	MYOVANT SCIENCES	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan, 2024 (11 months from now)
US7300935	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Jan, 2024 (11 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Feb, 2024 (1 year, 4 days from now)
US10350170	MYOVANT SCIENCES	Solid preparation	Feb, 2036 (13 years from now)
US10449191	MYOVANT SCIENCES	Treatment of prostate cancer	Sep, 2037 (14 years from now)
US10786501	MYOVANT SCIENCES	Treatment of prostate cancer	Sep, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL